MYNZ
Mainz Biomed B.V. (MYNZ) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
R&D intensity near 9.7% of revenue suggests a relatively efficient innovation footprint versus peers, though it does not by itself indicate superior environmental management.
No direct emissions, energy, or waste disclosures were provided, limiting evidence of environmental controls versus peers and keeping the assessment at a moderate level.
A gross margin of 33.7% can support some operational efficiency, but without resource-use data it cannot be translated into a clear environmental advantage over peers.
The absence of leverage-related environmental pressure is neutral rather than positive, because it does not materially differentiate MYNZ from peers on environmental risk exposure.
Social
Stock-based compensation at 27.0% of revenue is high versus typical peers, which can align employees but also signals heavier dilution-related stakeholder trade-offs.
High R&D spend relative to revenue may support workforce skill development and product-related human capital, yet the provided data do not show peer-leading labor practices.
No workforce safety, turnover, diversity, or customer-impact metrics were provided, so social positioning versus peers remains only moderately evidenced.
The capital structure data do not indicate social risk mitigation, leaving MYNZ broadly in line with peers rather than clearly advantaged on social factors.
Governance
Zero debt-to-equity indicates limited balance-sheet leverage, which can reduce creditor pressure and improve governance flexibility versus more levered peers.
Stock-based compensation at 27.0% of revenue suggests meaningful dilution risk, which can weaken alignment with shareholders relative to peers with tighter pay discipline.
R&D intensity near 9.7% of revenue implies management prioritizes long-term development, but the data do not confirm stronger board oversight or disclosure quality.
With no direct evidence of controversies, audit issues, or control failures, governance appears broadly average rather than structurally weaker than peers.
Overall Score
MYNZ appears broadly average versus peers across ESG, with some support from low leverage and R&D intensity but limited disclosure on material non-financial risks.
Score Driver: High Stock-Based Compensation Relative To Revenue Is The Main Offset To Otherwise Neutral-To-Slightly Supportive ESG Indicators.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Mainz Biomed B.V.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.